Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
Open Access
- 28 July 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (15), 4005-4015
- https://doi.org/10.1158/1078-0432.ccr-10-0196
Abstract
Purpose: This study sought to define the recommended dose of JS1/34.5-/47-/GM-CSF, an oncolytic herpes simplex type-1 virus (HSV-1) encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF), for future studies in combination with chemoradiotherapy in patients with squamous cell cancer of the head and neck (SCCHN).Keywords
Other Versions
This publication has 21 references indexed in Scilit:
- Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeuticsCytokine & Growth Factor Reviews, 2010
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic MelanomaJournal of Clinical Oncology, 2009
- A multidisciplinary approach to squamous cell carcinomas of the head and neck: an updateCurrent Opinion in Oncology, 2008
- A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating FactorClinical Cancer Research, 2006
- Planned Post‐Chemoradiation Neck Dissection: Significance of Radiation DoseThe Laryngoscope, 2006
- Planned Neck Dissection after Concomitant Radiochemotherapy for Advanced Head and Neck CancerThe Laryngoscope, 2005
- Final Results of the 94–01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx CarcinomaJournal of Clinical Oncology, 2004
- Who merits a neck dissection after definitive chemoradiotherapy for N2–N3 squamous cell head and neck cancer?Head & Neck, 2003
- ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour propertiesGene Therapy, 2003
- An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck CancerJournal of Clinical Oncology, 2003